UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

CHAMPIONS BIOTECHNOLOGY, INC.

(Exact name of registrant as specified in its charter)

Delaware		0-17263		52-1401755
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

Science and Technology Park at Johns Hopkins 855 N. Wolfe Street, Suite 619, Baltimore, MD		21205
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (410) 369-0365

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

INFORMATION TO BE INCLUDED IN THE REPORT

Item 5.03.		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

(a) On February 18, 2011, in accordance with Section 109 of the General Corporation Law of the State of Delaware, Article IX of the Registrant’s Certificate of Incorporation, and Article IX of the Registrant’s original Bylaws, the Registrant’s Board of Directors repealed the Registrant’s original Bylaws and adopted new Bylaws.

Item 9.01.		Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed herewith:

Exhibit No.
3.1		Bylaws, as amended February 18, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.